A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT06929286 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Non-Muscle Invasive Bladder Cancer

Interventions

DRUG: Nadofaragene Firadenovec
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Memorial Sloan Kettering Cancer Center